SEARCH

SEARCH BY CITATION

References

  • 1
    Dienstag JL, McHutchison JG. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 22530.
  • 2
    Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 5 (5 Suppl. 1): S219.
  • 3
    McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 88492.
  • 4
    Ray SC, Arthur RR, Carella A, et al. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182: 698707.
  • 5
    Al Faleh FZ, Huraib S, Sbeih F, et al. Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia. J Viral Hepat 1995; 2: 2936.
  • 6
    Shobokshi OA, Serebour FE, Skakni L, et al. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999; 58: 448.
  • 7
    Koshy A, Madda JP, Marcellin P, et al. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol 2002; 35: 825.
  • 8
    Fretz C, Jeannel D, Stuyver L, et al. HCV infection in a rural population of the Central African Republic (CAR): evidence for three additional subtypes of genotype 4. J Med Virol 1995; 47: 4357.
  • 9
    Oni AO, Harrison TJ. Genotypes of hepatitis C virus in Nigeria. J Med Virol 1996; 49: 17886.
  • 10
    Sanchez Quijano A, Abad MA, Torronteras R, et al. Unexpected 10. high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol 1997; 27: 259.
  • 11
    Matera G, Lamberti A, Quirino A, et al. Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn Microbiol Infect Dis 2002; 42: 16973.
  • 12
    Remy AJ, Verdier E, Perney P, et al. Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country. J Hepatol 1998; 29: 169.
  • 13
    NIH. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 146.
  • 14
    Diago M, Hadziyannis SJ, Bodenheimer H, et al. Optimized virological response in genotype 4 chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) (pegasys®) in combination with ribavirin (RBV). Hepatology 2002; 2: 364A.
  • 15
    Shobokshi OA, Serebour FE, Skakni L, et al. Combination therapy of peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia. Hepatology 2003; 384 (Suppl. 1): 636A.
  • 16
    Alfaleh FZ, Hadad Q, Khuroo MS, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 56874.
  • 17
    Esmat G, Abouzied AM, Abdel Aziz F, et al. Treatment with PEG-interferon alfa-2b (PEG-IFN) plus ribavirin compared to interferon alfa-2b (IFN alfa-2b)plus ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4. Hepatology 2002; 2: 364A.
  • 18
    Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 17337.
  • 19
    Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54: 125062.
  • 20
    Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int. 2011; 31 (Suppl. 1): 4552.
  • 21
    Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009; 49: 183846.
  • 22
    Yee HS, Currie SL, Tortorice K, et al. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study. Dig Dis Sci 2011; 56: 243948.
  • 23
    Nelson D, Rustgi VK, Balan V, et al. Sustained virologic response with albinterferon alfa-2b plus ribavirin treatment in prior interferon therapy nonresponders [abstract 51]. Hepatology 2007; 464 Suppl. 1: 256A.
  • 24
    Mohamed K. Ashour, Maissa E. Elraziky, Wafaa A, et al. Safety, Dosage and Efficacy of a Novel Y shaped molecule of Pegylated Interferon alpha 2a for Treatment of Chronic HCV. Accepted poster (AASLD 2011).
  • 25
    Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int. 2011; 31 (Suppl. 1): 6877.
  • 26
    Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment – finding the right path. Nat Rev Drug Discov 2007; 6: 9911000.
  • 27
    McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 182738.
  • 28
    McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292303.
  • 29
    Benhamou Y, Moussalli J, Ratziu V, et al. Results of a proof of concept study (C210) of Telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 4 HCV patients. J Hepatol 2009; 50: S6.
  • 30
    Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008; 52: 443241.
  • 31
    Jensen DM, Wedemeyer H, Herring RW, et al. High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12interim analysis from the PROPEL study. Hepatology 2010; 52: (abstract 81).
  • 32
    Elazar M, Liu M, McKenna SA, et al. The antihepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology 2009; 137: 182735.
  • 33
    Rossignol JF, Kabil SM, El Gohary Y, et al. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008; 28: 57480.
  • 34
    Mederacke I, Wedemeyer H. Nitazoxanide for the treatment of chronic hepatitis C New opportunities but new challenges? Ann Hepatol 2009; 8: 1668.
  • 35
    Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009; 49: 14608.
  • 36
    Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 15617.
  • 37
    Beinhardt S, Rasoul-Rockenschaub S, Matthias Scherzer T, et al. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in patient with chronic hepatitis C. J Hepatol 2010; 54: 5912.
  • 38
    Abu-Mouch SM, Fireman Z, Jarchovsky J, et al. The beneficial effect of vitamin D with combined peginterferon and ribavirin for chronic HCV infection. Presented at The Liver Meeting 2009: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): Abstract LB20. November 2, 2009.
  • 39
    Qiu D, Lemm JA, O'Boyle DR 2nd, et al. HCV NS5A Inhibitors Modulate Multiple Aspects of NS5A Expression. J Gen Virol 2011; 92: 250211.
  • 40
    Hézode C, Hirschfield GM, Ghesquiere W, et al. A NS5A replication complex inhibitor, combined with PEG-Interferon-Alpha-2A and ribavirin in treatment-naïve HCV-Genotype 1 or 4 subjects: The phase 2B momentum study week 12 results. Accepted poster (AASLD 2011).
  • 41
    Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2011; in press.